Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study

Angiogenesis inhibitors are of considerable interest for treating metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of apatinib in chemotherapy-refractory mCRC. Apatinib 500 mg was administered daily to patients who had progressed after two or more lines of standard f...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fen, Yuan, Xia, Jia, Jun, Bi, Xiaoxia, Zhou, Zeqiang, Zhou, Qiming, Li, Xia, Luo, Changguo, Deng, Minghui, Yi, Liangjie, Li, Yong, Lu, Jianxin, Su, Wenzhi, Chen, Hanbin, Zhu, Yu, Wang, Shubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142071/
https://www.ncbi.nlm.nih.gov/pubmed/32269247
http://dx.doi.org/10.1038/s41598-020-62961-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142071/
https://www.ncbi.nlm.nih.gov/pubmed/32269247
http://dx.doi.org/10.1038/s41598-020-62961-5

Ejemplares similares